Timothy Schmid
Insider (Form 4 reporting owner): EVP, WW Chair, MedTech CIK 1998491Name as filed: Schmid TimothyIts filings on EDGARAll insiders
Measures activity, not value. Not investment advice.
Since 18 Feb 2025, sold $15.1M in 4 sales of Johnson & Johnson.
Companies
Role on the latest Form 4 for each; open-market trades counted| Company | Role | Trades from | to | Purchases | Sales |
|---|---|---|---|---|---|
| Johnson & Johnson JNJ | EVP, WW Chair, MedTech | 18 Feb 2025 | 2 Sep 2026 | – | 4$15.1M |
What the share price did after their trades Share price return after each open-market trade, from the first close after the Form 4 became public, minus the return of the company's sector fund (the S&P 500 fund when the sector has none) over the same days. Median over the trades, in percentage points; at most one trade per company, side and month. It describes the past.
Median return minus the sector fund, in percentage points; "too few trades" under 5| Open-market trades | After 3 months | After 6 months | After 12 months |
|---|---|---|---|
| After sales | too few trades2 trades | too few trades2 trades | too few trades1 trade |
For a sale, a negative number means the shares did worse than the sector afterwards. It describes the past, not what comes next.
By year
Counted open-market trades, by trade date| Year | Purchases | Bought | Sales | Sold | Net |
|---|---|---|---|---|---|
| 2026 | – | – | 3 | $15.1M | -$15.1M |
| 2025 | – | – | 1 | $63K | -$63K |
Every trade
4, newest first; open-market purchases and sales only| Trade date | Company | Side | Shares | Price | Value | Planned Rule 10b5-1 plan: the insider set the trade up in advance, so its timing says less about their view. The box exists on Form 4 since April 2023. | Filing |
|---|---|---|---|---|---|---|---|
| 2 Sep 2026 | Johnson & Johnson JNJ | Sellafter exercising options | 33,597 | $274.74 | $9.2M | No | Form 4filed 4 Sep 2026 |
| 20 Feb 2026 | Johnson & Johnson JNJ | Sell | 1,322 | $245.66 | $325K | No | Form 4filed 23 Feb 2026 |
| 18 Feb 2026 | Johnson & Johnson JNJ | Sellafter exercising options | 22,623 | $244.33 | $5.5M | No | Form 4filed 18 Feb 2026 |
| 18 Feb 2025 | Johnson & Johnson JNJ | Sellafter exercising options | 403 | $156.15 | $63K | No | Form 4filed 18 Feb 2025 |
From Form 4: open-market purchases (code P) and sales (code S) only; awards, option exercises, tax withholding and gifts are not counted. Greyed rows are amended copies or another filer's report of the same trade and count nowhere. Measures activity, not value. Not investment advice.